

1 **Validation Study of HLA-B*13:01 as a Biomarker of Dapsone Hypersensitivity Syndrome**
2 **in Leprosy Patients in Indonesia**

3
4 Hana Krismawati^{1,*}, Astrid Irwanto^{2,*}, Arry Pongtiku³, Ishak Darryl Irwan², Yustinus Maldan¹,
5 Yuli Arisanti Sitanggang¹, Tri Wahyuni¹, Ratna Tanjung¹, Yonghu Sun⁴, Hong Liu⁴,
6 Furen Zhang⁴, Antonius Oktavian¹, Jianjun Liu, PhD^{2,□}.

7 *Denotes equal contribution

8 †Corresponding author

9

10 ¹Institute of Research and Development for Biomedicine Papua, National Institute of Health
11 Research and Development, Ministry of Health Republic of Indonesia

12 ²Human Genetics, Genome Institute of Singapore, Agency for Science, Technology and
13 Research, Singapore

14 ³Faculty of Public Health Medicine, University of Cendrawasih Papua; Netherlands Leprosy
15 Relief Indonesia

16 ⁴Shandong Provincial Institute of Dermatology and Venereology & Provincial Hospital for Skin
17 Diseases, Shandong First Medical University & Shandong Academy for Medical Sciences, Jinan,
18 Shandong

19

20 †**Corresponding Author:**

21 Jianjun Liu, PhD

22 Group Leader, Human Genetics 2, Genome Institute of Singapore,

23 Agency for Science, Technology and Research

24 Address: 60 Biopolis Street, #02-01, Genome, Singapore 138672

25 Email: liuj3@gis.a-star.edu.sg

26 Contact No: +65-68088088

27

28 **Word Count:** 2511

29 **KEY POINTS**

30

31 **Question:** Can *HLA-B*13:01* be a predictor of Dapsone Hypersensitivity Syndrome in
32 Indonesians?

33 **Findings:** In this case control validation study, *HLA-B*13:01* is significantly associated with
34 DHS in Indonesians and can predict a person at risk of DHS 95% of the time.

35 **Meaning:** *HLA-B*13:01* is validated as a biomarker for DHS in Indonesians and can be useful to
36 screen and prevent further incidences of DHS in the population.

37

38 **ABSTRACT**

39

40 **Importance:** Leprosy is a stigmatizing, chronic infection which degenerates the nervous system
41 and often leads to incapacitation. Multi-drug therapy (MDT) which consists of dapsone,
42 rifampicin and clofazimine has been effective to combat this disease. In Indonesia, leprosy is
43 still a problem. Furthermore, there had been reports of Dapsone Hypersensitivity Syndrome
44 (DHS) which also challenges leprosy elimination in certain aspects. *HLA-B*13:01* has been
45 found to be associated with DHS and prospective screening has proven its ability to prevent
46 DHS in the Chinese population, but has not been validated in Indonesians.

47

48 **Objective:** To validate *HLA-B*13:01* as a biomarker for DHS in the Indonesian population.

49

50 **Design:** This is a case-control study.

51

52 **Setting:** Population-based, multi-district recruitment from primary care centers in two of the top
53 3 most prevalent provinces in Indonesia, Papua and West Papua.

54

55 **Participants:** Leprosy patients who presented themselves with DHS were recruited as case
56 subjects (34 cases) and leprosy patients without DHS were recruited as control subjects (52
57 controls).

58

59 **Exposure:** Leprosy patients who had undergone multi-drug treatment for leprosy under the
60 standard WHO guideline, consisting of rifampicin, dapsone and clofazamine.

61

62 **Main Outcome and Measures:** The association of *HLA-B*13:01* to DHS based on difference in
63 allele frequencies between cases and controls. HLA-B alleles were typed using the gold-
64 standard Sequence Based Typing method. Results were analyzed using logistic regression and
65 risk assessment was carried out.

66

67 **Results:** The results of HLA-typing showed that *HLA-B*13:01* was the most significant allele
68 associated with DHS, with odds ratio=247.6 and P-value=4.81E-9, confirming the strong
69 association of *HLA-B*13:01* to DHS in the Indonesian population. The sensitivity of this
70 biomarker is 91.2% and specificity is 96.2%, with an area under the curve of 0.95.

71

72 **Conclusions and Relevance:** *HLA-B*13:01* is validated as a biomarker for DHS in leprosy
73 patients in Indonesia, and can potentially be a good predictor of DHS to help prevent this
74 condition in the future.

75

76 **Keywords:** HLA-B*13:01, dapsone hypersensitivity syndrome, leprosy, dapsone, adverse drug
77 reaction, Papua, Indonesia

78

79

80

81

82 BACKGROUND

83 In the era of leprosy elimination, many efforts have been done by the government to
84 combat leprosy¹. Multi-drug treatment (MDT) supplied by the World Health Organization is
85 intensively applied as the main treatment of leprosy in every region in Indonesia. Although the
86 availability of data is scarce, many cases of Dapsone Hypersensitivity Syndrome (DHS) were
87 reported from districts in Papua and oftentimes are fatal cases.

88 Dapsone is an antibiotic and anti-inflammatory agent used for the prevention and
89 treatment of infectious and chronic inflammatory diseases. As an antibiotic, dapsone is used to
90 treat leprosy, malaria, actinomycetoma as well as *Pneumocystis jirovecii* pneumonia in persons
91 with human immunodeficiency virus (HIV), whereas as an anti-inflammatory agent, it's used to
92 treat dermatitis herpetiformis, linear IgA dermatosis, subcorneal pustular dermatosis and
93 erythema elevatum dilutinum^{2,3}. Among all these diseases, leprosy is currently the one that most
94 prevalently uses dapsone for treatment.

95 About 0.5-3.6% of persons treated with dapsone have drug hypersensitivity syndrome³⁻⁵,
96 which was first described by Lowe and Smith⁶ in 1949 and termed "dapsone hypersensitivity
97 syndrome" (DHS)⁷. The syndrome is a severe idiosyncratic drug reaction characterized by the
98 clinical manifestations of fever, rash, and systemic involvement (most commonly of the liver and
99 the hematologic system), which can cause severe organ dysfunction. DHS is usually manifested
100 4 to 6 weeks after the initiation of therapy.

101 With the introduction of MDT for leprosy worldwide and with the use of dapsone in
102 chemoprophylaxis for *P. jirovecii* pneumonia in HIV infection combined with
103 trimethoprim/sulfamethoxazole, the incidence of DHS might have also increased. On the basis
104 of a recent systematic review of the published epidemiologic studies, the estimated global
105 prevalence of the DHS is 1.4%, and the associated mortality is 9.9%⁸. This review also showed
106 that 72.5% of the global DHS incidence actually originated in Asia and 71.8% of these DHS
107 cases happened in leprosy patients. A recent literature review for DHS in China concluded a
108 prevalence of 1.5% and mortality rate of 9.6%, very close to the global estimate for DHS⁹.

109 Previous study on the genetic determinant of DHS in 2,141 Chinese leprosy samples
110 has discovered the risk factor for DHS¹⁰. They found that a single DNA variant, located in an
111 immunity-associated gene called HLA-B, was significantly more common in those who
112 developed DHS. Individuals with one copy of *HLA-B*13:01* risk variant are 34 times more likely
113 to develop DHS than individuals without. Two copies of *HLA-B*13:01* makes individuals 101
114 times more susceptible to the syndrome. The results have been independently validated in
115 various Asian populations including Thais¹¹, Koreans¹², Indians¹³ and Taiwanese¹⁴. Screening

116 for this allele in new leprosy patients before the initiation of MDT has proven beneficial to reduce
117 incidence rate of DHS in China to zero¹⁵.

118 In this study we aim to validate *HLA-B*13:01* as a biomarker for DHS in the Indonesian
119 population, report the allele frequency of *HLA-B*13:01* in Indonesia, and confirm the sensitivity
120 of *HLA-B*13:01* as a predictor of DHS in this population.

121

122 **METHODS**

123 Study Design

124 This is a case-control genetic association study that collected retrospective leprosy patients who
125 had survived DHS ('cases') and those whom did not exhibit DHS but has completed at least 6
126 months of multi-drug treatment for leprosy ('controls').

127

128 Study population

129 The study was carried out in main pockets district of Papua (Jayapura and Biak) and West
130 Papua (Bintuni, Manokwari and Sorong) provinces in Indonesia.

131

132 Ethical Clearance

133 Ethical approval was obtained from National Institute of Health Research and Development with
134 reference number LB. 02.01/5.2/KE.065/2016.

135

136 Subject Recruitment

137 The patients were recruited by inviting them to the point of care or visiting their homes. The
138 informed consent was explained and given to the patient to read. The information sheet
139 attached to the consent form contained the study aim, participant's eligibility, risks and benefits
140 of participation, as well as confidentiality of data. The patients who agreed to participate in the
141 study signed the inform consent in front of a researcher, a health worker and one family
142 member as witnesses.

143

144 Subject Recruitment Criteria

145 Leprosy patients treated with MDT who developed DHS symptoms were designated as 'cases'.
146 These patients exhibit symptoms as described by Richardus and Smith¹⁶ which include: (1)
147 presence of at least two symptoms: fever, skin eruption, lymphadenopathy and liver
148 abnormalities (elevated transaminases by at least 2 times); (2) symptoms appearing between
149 the second and eighth week after the commencement of dapsone and disappearing upon

150 discontinuation of the drug; (3) symptoms not ascribed to any other drug given simultaneously;
151 (4) symptoms not attributable to leprosy reactions; (5) no other diseases liable to cause similar
152 symptoms. Leprosy patients treated with MDT who did not develop any hypersensitivity
153 reactions after 6-24 months of MDT treatment was designated as 'controls'. Each case has at
154 least one control obtained from the same area. The clinical information of the patients as well as
155 the demographic and geographic origin were obtained. We took only one patient in each family
156 based on their family name to ensure that all the samples were independent of each other and
157 the genetic results we see are not due to familial segregation. The final number of cases and
158 control that were collected are 34 cases and 55 controls, i.e. 14 cases and 28 controls from
159 Papua province and 20 cases and 24 controls from West Papua province.

160

161 DNA extraction and Quantification

162 5 ml of EDTA anticoagulated venous blood was collected from all participants. The blood tubes
163 were stored at -20°C and transferred in chilled (4°C) condition to Institute of Research and
164 Development for Biomedicine Papua (IRDBP). At IRDBP, genomic DNA was extracted from the
165 blood lymphocytes by a standard procedure using QIAGEN QIAamp DNA blood maxi kit
166 (Catalog No. 51194). We modified the procedure from the manual to get the optimum yield, i.e.
167 prolonged the incubation period on 70°C for 2 hours instead of 10 minutes. The DNA yield was
168 quantified using Nanodrop™ Spectrophotometry.

169

170 HLA Sequence Based Typing (SBT)

171 All of the samples were typed using a research-use-only (RUO) version of an approved (CE-IVD)
172 HLA-typing kit commercially available from TBG Diagnostics Limited, which is called HLAssure
173 SE B Locus SBT Kit (Catalog No. 50210). This kit is a direct sequence-based typing approach,
174 which is done by Sanger sequencing and considered as gold-standard for HLA typing. The kit is
175 designed to detect all known polymorphic positions in exons 2 and 3 of HLA-B, which are
176 necessary for accurate allelic determination. We followed the manufacturer's instructions for the
177 HLA-typing experiment protocol. Results from the sequencing is processed through a licensed
178 software that comes with the kit, called AccuType™ Software. Analysis procedure and
179 interpretation followed the software's instruction manual.

180

181 Power calculation

182 We assessed power using QUANTO¹⁷ for the validation of the *HLA-B*13:01*, assuming a similar
183 odds ratio (OR) with the initial discovery in Chinese¹⁰ applies to the Indonesians (Figure 1).

184 Assuming the frequency of *HLA-B*13:01* in Indonesians is around 2% (similar to the Chinese),
185 the sample size to analyze in this proposed study will have a good power (> 0.8) to capture the
186 associations of *HLA-B*13:01* at a type-1 error rate of 5% if we have at least 15 cases and 15
187 controls. Therefore, our collection of 34 cases and 55 controls are well powered to detect a
188 positive association.

189

190 Statistical Analysis

191 Data analysis was done using R, which is a dedicated statistical and data management tool for
192 genetic analysis. Association test of *HLA-B*13:01* and DHS was done by performing logistic
193 regression.

194

195 Interpretation of Results

196 P-value was interpreted as the statistical significance of the test results as compared to by
197 chance alone. A small p-value (<0.05) indicates evidence against the null hypothesis of no
198 association, hence it will be rejected, whereas a large p-value (>0.05) indicates weak evidence
199 against the null hypothesis, hence we fail to reject it. Odds ratio (OR) is a relative measure of
200 effect comparing the DHS cases relative to the non-DHS cases. If the OR equals to 1, it implies
201 no difference between the two groups.

202

203 **RESULTS**

204 In this study we recruited 34 leprosy patients with DHS as cases and 55 leprosy patients without
205 DHS as controls. One control failed to have a good quality DNA; yellow extract with a 260/280
206 OD ratio of 1.31. Excluding this sample, we had 34 cases and 54 controls typed on the
207 HLAssure B Locus kit. Unfortunately, two other controls were not able to be sequenced
208 successfully as only 25% of the reads were unable to be mapped on the AccuType™ Software,
209 and it failed to distinguish which HLA-B alleles these sample carry. Finally, excluding all the
210 failed samples, 34 cases and 52 controls with successful HLA-B typing results were brought for
211 further analyses.

212

213 *HLA-B*13:01* is the most associated allele with DHS in Papuans

214 Based on the result of the SBT, we can see a spectrum of HLA-B allele frequency in the leprosy
215 patients from Papua (Table 1). We performed a log additive test (logistic regression) to observe
216 the association of all the identified HLA-B alleles to DHS, but we discovered that only *HLA-*
217 *B*13:01* allele showed association with DHS. *HLA-B*13:01* is present in 50% of the cases, 1.9%

218 of the controls and the difference between the two groups is significant ($P=4.81\times 10^{-9}$; odds
219 ratio=247.65), surpassing the genome-wide significance threshold. When the region where the
220 samples came from was considered as a potential confounding factor (Papua or West Papua
221 province), the adjusted P-value and odds-ratio of *HLA-B*13:01* is considered unaffected
222 (adjusted $P=7.85\times 10^{-9}$; odds ratio=255.39), indicating that the evidence of association was not
223 driven by the effect of population stratification.

224

225 *HLA-B*13:01* as a risk predictor for DHS in Papuans

226 There were 31 carriers and 3 non-carriers of *HLA-B*13:01* among the DHS cases; whereas
227 among the controls, there were 2 carriers and 50 non-carriers (Table 2). In other words, *HLA-*
228 *B*13:01* was present in 91.2% of case patients and 3.8% of the controls. This suggests that
229 *HLA-B*13:01* had a sensitivity of 91.2% and specificity of 96.2% as a predictor of DHS.
230 However, we also observed a significant deviation of the genotype frequency of *HLA-B*13:01* in
231 the case patients ($P=0.00039$), unlike the controls ($P=1$).

232

233 Using *HLA-B*13:01* as a predictor of DHS risk in Papuans, we observed that the area under the
234 curve (AUC) = 0.95, which means that *HLA-B*13:01* can correctly classify people with and
235 without risk of developing DHS 95% of the time (Figure 2). Consequently, the risk carried by a
236 person who has at least one copy of *HLA-B*13:01* allele (heterozygous odds ratio) is then 233.3
237 times higher than the risk of those who do not carrying any copy of *HLA-B*13:01* allele.
238 Assuming that the prevalence of DHS in Papua is similar to the estimated global prevalence of
239 1.4%⁸, *HLA-B*13:01* would have a positive predictive value (PPV) of 25.4% and a negative
240 predictive value (NPV) of 99.9% in identifying people at risk to DHS. To prevent one case of
241 DHS, we would theoretically need to screen 79 leprosy patients and hence we could reduce
242 DHS risk by 10-fold (from 1.4% to 0.13%). Our data from 2016 in Papua has shown that the
243 incidence of DHS among leprosy patients is 10-times higher than the global estimate (~11%).
244 This translates to a PPV of 74.8%, NPV of 98.9%, and 10 people needed to screen to prevent
245 one case of DHS.

246

247 **DISCUSSION**

248 In this study, we replicated the association of with dapsone hypersensitivity syndrome in the
249 Indonesian population, where Papua and West Papua provinces were selected as they are
250 considered top three largest leprosy pockets in Indonesia with a prevalence of 4,06 per 10,000
251 population in Papua and 11,48 per 10,000 population in West Papua. These two areas are also

252 considered as focus community areas in the National Program for Leprosy Elimination. In terms
253 of DHS, according to an unpublished annual local report, Papua has an incidence between 2-
254 10% per year. Besides, the neighboring country sharing the same island as Papua has shown
255 to have the highest reported allele frequency in the world (28%), unlike other major ethnicities in
256 Indonesia, such as Javanese and Sundanese (1.5%) and Riau population (5.4%)¹⁸.

257
258 Initially discovered as a risk factor and predictor of DHS in the Chinese population¹⁰, *HLA-*
259 *B*13:01* has been shown in multiple other studies in Asia as being a strong predictor to the
260 same condition^{11-14,19}. It has also been shown to be associated with dapsona hypersensitivity
261 syndrome occurring in non-leprosy patients in Thailand¹¹. Compared to the studies in Chinese
262 and Thais, the odds ratio we discovered in Papuans are 12-times what was reported in
263 Chinese¹⁰ and 4.6-times what was reported in Thais¹¹. Presumably, the abundance of *HLA-*
264 *B*13:01* in Papuans contribute to the high odds ratio we see in this population. In Chinese, the
265 frequency of *HLA-B*13:01* ranges between 3-8% across North and South China, but for the
266 Melanesians and Australian Aboriginals who are evolutionary related to Papuans, the allele
267 frequency may reach up to 28%¹⁸.

268
269 Similar to the publication in the Chinese population¹⁰, we found a significant deviation of *HLA-*
270 *B*13:01* genotype frequency from Hardy Weinberg equilibrium in only the case patients
271 ($P=3.9 \times 10^{-4}$). We also think the reason for this is due to the potential oversampling as the effect
272 of the highly penetrant *HLA-B*13:01* as a susceptibility factor for DHS and the bias towards
273 sampling only the surviving DHS patients. Although not very well documented, the mortality rate
274 for DHS in Papua is estimated to be quite high. Many of the patients come from rural areas and
275 oftentimes they were treated after active case findings into their home villages. Upon drug
276 delivery, any side effect that occur to them were often not reported. Patients even think these
277 side effects were curses instead of a medical condition. Hence, with not much understanding of
278 the disease and potential side effects, many of the fatal cases would have been missed and
279 being under-reported.

280
281 Until now, there is no preventive action to reduce DHS incidence that been implemented in
282 hospitals as well as in point of care clinics to prevent DHS in Indonesia. The DHS treatment is
283 performed with intensive care at the time DHS symptoms appear, and it may be due to the
284 patient being warded for several days up to weeks. Besides the lack of knowledge and public
285 awareness of DHS, Indonesia's geographic landscape adds as a challenge for patients who

286 need immediate treatment upon a severe adverse reaction. There have been reported deaths in
287 DHS patients due to delays in handling and some community perceptions that stigmatizes DHS
288 as a curse instead of a form of an adverse drug effect. The incidence of DHS case in the family
289 or community also causes trauma as well as rejection to undergo MDT. This issue affects
290 leprosy elimination program especially in endemic areas of leprosy in Indonesia. Screening of
291 *HLA-B*13:01* among leprosy patients before treatment can be valuable in many aspects:
292 clinically to prevent DHS and its related mortality, socially to prevent trauma of losing family
293 members and experiencing severe hypersensitivity, and in public health perspective to increase
294 compliance to treatment and reduce transmission for reaching the goal of national elimination
295 program.

296

297 **LIMITATION**

298 As a case-control population-based study, participants were recruited based on pass history of
299 DHS diagnosis as written in the medical record. The limitation to this is that misdiagnosis of
300 DHS may have happened and there will be no way to verify this real-time. However, to alleviate
301 this issue, during sample collection we visited the subject and conducted in-depth interview
302 accompanied by the attending physician and/or medical doctor who diagnosed and treated the
303 subject when DHS had manifested.

304

305 **CONCLUSION**

306 *HLA-B*13:01* is validated as a biomarker for DHS in leprosy patients in Indonesia. Screening for
307 *HLA-B*13:01* may potentially reduce DHS incidence significantly and benefit many aspects of
308 the leprosy control program in Indonesia.

309

310

311 **ACKNOWLEDGEMENTS**

312 We thank all the individuals who had participated in this project. This work was funded by grants
313 from the National Key Research and Development Program of China (2016YFE0201500),
314 Genome Institute of Singapore, Agency for Science Technology and Research, and National
315 Institute of Health Research and Development, Ministry of Health Republic of Indonesia.

316

317 **REFERENCES**

- 318 1. Peters RMH, Dadun, Lusli M, et al. The Meaning of Leprosy and Everyday Experiences:
319 An Exploration in Cirebon, Indonesia. *Journal of Tropical Medicine*. 2013;2013:10.
- 320 2. Wozel VE. Innovative use of dapsone. *Dermatol Clin*. 2010;28(3):599-610.
- 321 3. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. *J Am*
322 *Acad Dermatol*. 2001;45(3):420-434.
- 323 4. Rao PN, Lakshmi TS. Increase in the incidence of dapsone hypersensitivity syndrome--
324 an appraisal. *Lepr Rev*. 2001;72(1):57-62.
- 325 5. Leslie KS, Gaffney K, Ross CN, Ridley S, Barker TH, Garioch JJ. A near fatal case of
326 the dapsone hypersensitivity syndrome in a patient with urticarial vasculitis. *Clin Exp*
327 *Dermatol*. 2003;28(5):496-498.
- 328 6. Lowe J, Smith M. The chemotherapy of leprosy in Nigeria; with an appendix on glandular
329 fever and exfoliative dermatitis precipitated by sulfones. *Int J Lepr*. 1949;17(3):181-195.
- 330 7. Allday EJ, Barnes J. Toxic effects of diaminodiphenylsulphone in treatment of leprosy.
331 *Lancet*. 1951;2(6675):205-206.
- 332 8. Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic
333 review. *Acta Derm Venereol*. 2012;92(2):194-199.
- 334 9. Wang N, Parimi L, Liu H, Zhang F. A Review on Dapsone Hypersensitivity Syndrome
335 Among Chinese Patients with an Emphasis on Preventing Adverse Drug Reactions with
336 Genetic Testing. *Am J Trop Med Hyg*. 2017;96(5):1014-1018.
- 337 10. Zhang FR, Liu H, Irwanto A, et al. HLA-B*13:01 and the dapsone hypersensitivity
338 syndrome. *N Engl J Med*. 2013;369(17):1620-1628.
- 339 11. Tempark T, Satapornpong P, Rerknimitr P, et al. Dapsone-induced severe cutaneous
340 adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai
341 population. *Pharmacogenet Genomics*. 2017;27(12):429-437.
- 342 12. Cai F, Lucas M, Yun J. Dapsone-induced drug reaction with eosinophilia and systemic
343 symptoms associated with HLA-B*13:01. *Intern Med J*. 2018;48(3):363-364.
- 344 13. Chiramel MJ, et al. Case-control study measuring the association between HLA-B*13:01
345 and dapsone hypersensitivity syndrome in Indian patients. *Leprosy Review* 90: 371-377,
346 No. 4, Dec 2019.
- 347 14. Chen WT, Wang CW, Lu CW, et al. The Function of HLA-B*13:01 Involved in the
348 Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions. *J Invest*
349 *Dermatol*. 2018;138(7):1546-1554.
- 350 15. Liu H, Wang Z, Bao F, et al. Evaluation of Prospective HLA-B*13:01 Screening to
351 Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy. *JAMA Dermatol*.
352 2019.
- 353 16. Richardus JH, Smith TC. Increased incidence in leprosy of hypersensitivity reactions to
354 dapsone after introduction of multidrug therapy. *Lepr Rev*. 1989;60(4):267-273.
- 355 17. W G, J M. *QUANTO documentation*. (Technical report no. 157). In:2012.
- 356 18. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a
357 database and online repository for immune gene frequencies in worldwide populations.
358 *Nucleic Acids Res*. 2011;39(Database issue):D913-919.
- 359 19. Wang H, Yan L, Zhang G, et al. Association between HLA-B*1301 and dapsone-induced
360 hypersensitivity reactions among leprosy patients in China. *J Invest Dermatol*.
361 2013;133(11):2642-2644.
- 362 20. Williams DL, Spring L, Harris E, Roche P, Gillis TP. Dihydropteroate synthase of
363 *Mycobacterium leprae* and dapsone resistance. *Antimicrob Agents Chemother*.
364 2000;44(6):1530-1537.
- 365 21. Watanabe H, Watanabe Y, Tashiro Y, et al. A docking model of dapsone bound to HLA-
366 B*13:01 explains the risk of dapsone hypersensitivity syndrome. *J Dermatol Sci*.
367 2017;88(3):320-329.
- 368

369 **Abbreviations**

370 DHS, dapsone hypersensitivity syndrome

371 DNA, deoxyribonucleic acid

372 HLA, Human Leukocyte Antigen

373 MDT, multi-drug treatment

374 OR, odds ratio

375

376 **List of Tables**

377 Table 1. Allele frequency spectrum of Papua Population

HLA-B alleles	AF controls (n=52)	AF cases (n=34)	AF ALL (n=86)	P-value	OR	95% CI
13:01	0.019	0.5	0.209	4.81×10⁻⁹	247.65	1.73-69.36
15:02	0	0.015	0.006	0.991		
15:06	0.094	0	0.058	0.084		
15:12	0.009	0	0.006	0.991		
15:21	0.160	0.061	0.122	0.150		
15:25	0	0.015	0.006	0.992		
15:195	0.009	0	0.006	0.990		
18:01	0.160	0.091	0.134	0.099		
18:02	0	0.015	0.006	0.991		
18:105	0	0.015	0.006	0.991		
27:04	0.038	0	0.023	0.989		
27:06	0.019	0	0.012	0.992		
35:01	0	0.015	0.006	0.991		
35:05	0.038	0.015	0.029	0.404		
35:30	0.009	0	0.006	0.992		
38:02	0.132	0.030	0.093	0.046		
38:46	0	0.015	0.006	0.991		
39:01	0	0.015	0.006	0.991		
40:01	0.057	0.076	0.064	0.893		
40:02	0.028	0	0.017	0.991		
40:10	0.009	0.030	0.017	0.323		
40:11	0.009	0	0.006	0.992		
40:89	0.009	0	0.006	0.992		
40:99	0.009	0	0.006	0.992		
40:143	0.009	0	0.006	0.992		
48:01	0.009	0.061	0.029	0.084		
56:01	0.066	0	0.041	0.991		
56:02	0.009	0	0.006	0.992		
56:07	0.075	0.030	0.058	0.224		
58:59	0.009	0	0.006	0.992		

378 AF, allele frequency.

379

380 Table 2. The allele Frequency and Hardy Weinberg P-Value

<i>HLA-B*13:01</i>	Non-carrier	Heterozygous	Homozygous	Allele Frequency	HWE P-value
DHS + (N=34)	3 (8.82%)	28 (82.35%)	3 (8.82%)	50%	0.00039
DHS - (N=52)	50 (96.15%)	2 (3.85%)	0 (0%)	1.92%	1

381


382

383

384 **List of Figures**

385


386 Figure 1. The power is estimated for various allele frequencies (0.01 to 0.1) and effect sizes
387 (OR=15, 20 and 25).



388

389

390 Figure 2. Receiver-operating curve for an additive prediction model of DHS using *HLA-B*13:01*
391 allele as predictor in Papuans. AUC, area under the curve. Overall sensitivity is 91.2% and
392 specificity is 96.2%.



393

394